Centiva Capital’s Nephros NEPH Stock Holding History

Centiva Capital’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,835	Closed	-$52.9K	–	1901
2025 Q4	$52.9K	Buy	+10,835	New	+$55.4K	﹤0.01%	1138

Other funds holding NEPH

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Cornerstone Capital Palo Alto, California $1B AUM 21.47% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Centiva Capital's NEPH Position: Q1 2026 in Review

Centiva Capital sold out of Nephros (NEPH) in Q1 2026, closing a stake of 10,835 shares — an estimated $52.9K sold.

Centiva Capital first reported a position in NEPH in Q4 2025 and held it in 1 quarter. The position peaked at $52.9K in Q4 2025. 27 funds tracked by Wall St. Rank hold NEPH as of Q1 2026.

Centiva Capital reported no remaining Nephros position as of Q1 2026 after selling out during the quarter.
Centiva Capital sold 10,835 Nephros shares in Q1 2026, an estimated $52.9K.
Centiva Capital first reported a position in Nephros in Q4 2025 and held it in 1 quarter.
Centiva Capital's Nephros position peaked at $52.9K in Q4 2025.
27 funds tracked by Wall St. Rank held Nephros as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.